Novartis closely monitors US reciprocal tariff policy amid global trade uncertainty
Novartis is closely monitoring the U.S. reciprocal tariff policy, which may impose 25% tariffs on pharmaceuticals. The company plans to expand in Japan with radiopharmaceutical production by 2026 and recently acquired Mariana Oncology for $1B to strengthen its oncology portfolio.

